Pharmaceuticals News and Research

RSS

Patent applications for Shrink's stem cell research and drug discovery tool StemDisc filed

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that patent applications for its stem cell research and drug discovery tool StemDisc have been filed.

24 May 2010

Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval by the Swedish Medical Products Agency to commence a Phase I/IIa clinical trial with Lytixar (LTX-109) for nasal decolonisation of MRSA.

24 May 2010

ICON announces acquisition of Timaq Medical Imaging

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has acquired Timaq Medical Imaging, a leading European provider of advanced imaging services to pharmaceutical and biotech firms.

24 May 2010

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, today announced new findings on once-daily INTUNIV (guanfacine) Extended Release Tablets, the first selective alpha-2A agonist approved for the treatment of Attention Deficit Hyperactivity Disorder, at a major psychiatric meeting.

24 May 2010

Health leaders discuss polio, alcohol, childhood obesity at WHA

From the 63rd World Health Assembly (WHA) in Geneva, the Associated Press reports on what some "describe as a new strategy to get rid of" polio that focuses on developing solutions to "problems in each country, provides more WHO monitoring, like more teleconferences, and holds governments more accountable." The plans also provide "[n]ew [polio] outbreak response plans," according to the AP.

24 May 2010

New MALDI molecular imaging system offers spatial analysis of target metabolites

At the 58th ASMS Conference on Mass Spectrometry and Allied Topics, Bruker today announces a novel MALDI molecular imaging system based on the extreme performance of the solariX FTMS.

24 May 2010

Groundwater contaminants present potential health concern

More than 20 percent of untreated water samples from 932 public wells across the nation contained at least one contaminant at levels of potential health concern, according to a new study by the U.S. Geological Survey.

24 May 2010

Bayer Healthcare Pharmaceuticals presents Phase 3 clinical data on gadobutrol

Bayer HealthCare Pharmaceuticals, Inc. today announced presentation of data in a poster titled "Results from a multicenter, open-label Phase 3 study to determine the safety and efficacy of gadobutrol, a macrocyclic 1.0 molar GBCA in patients referred for contrast-enhanced MRI of the central nervous system (CNS)" at the 48th Annual Meeting of the American Society of Neuroradiology (ASNR) in Boston, MA.

24 May 2010

High family medical bills appear to reduce use of expensive medications: Study

People with rheumatoid arthritis whose health insurance requires them to pay a higher share of the cost are less likely to use biotech drugs than those with coverage that is more generous. High family medical bills also appear to reduce the use of these powerful but expensive medications, according to a new study in Health Services Research.

21 May 2010

New data on ARIAD's AP24534 and ridaforolimus accepted for presentation at ASCO 2010

ARIAD Pharmaceuticals, Inc. today announced that new data on AP24534, its investigational pan-BCR-ABL inhibitor, and ridaforolimus, its investigational mTOR inhibitor being developed by Merck, Sharpe & Dohme Corp., have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting.

21 May 2010

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that updates on several of its BiTE antibody development programs will be made at two upcoming medical conferences.

21 May 2010

Clinical data evaluating CAL-101 in patients with hematologic malignancies to be presented at ASCO 2010

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, today announced that updated clinical data evaluating CAL-101, an oral, PI3K inhibitor, in patients with hematologic malignancies, will be presented during a poster discussion session at the 2010 American Society of Clinical Oncology Annual Meeting taking place June 4-8, 2010 at McCormick Place in Chicago, IL.

21 May 2010

China BCT Pharmacy reports 5.2% increase in first-quarter 2010 revenue

China BCT Pharmacy Group, Inc., a leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceutical products in Guangxi Province, China, today announced results for the first quarter ended March 31, 2010.

21 May 2010

Ligand Pharmaceuticals secures milestone and royalty interest in IL-9 antibody program

Ligand Pharmaceuticals Incorporated announced today that it has purchased from the Genaera Liquidating Trust certain intellectual property and interests in future milestones and royalties for MEDI-528, an IL-9 antibody program under development by AstraZeneca's subsidiary, MedImmune. MEDI-528 is currently in a 320-patient Phase II study for moderate-to-severe asthma.

21 May 2010

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in hematology and oncology, today announced that clinical data on belinostat will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology, to be held June 4-8, 2010 at the McCormick Place Convention Center in Chicago, Illinois, as part of the ASCO proceedings.

21 May 2010

Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010

Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.

21 May 2010

Smoking cessation treatments effective and safe for people with schizophrenia

In a study published today in the journal Addiction, researchers have determined that treatment for smoking dependence is as effective among people with severe mental illnesses as it is for the general population. Importantly, they also found that offering such treatments does not appear to cause deterioration in mental health.

21 May 2010

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.

21 May 2010

Cord Blood America reviews first quarter results

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that its co-founder and CEO, Matthew Schissler, reviewed first quarter results and progress in an interview with analyst Francis Gaskins.

21 May 2010

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.

21 May 2010

Pharmaceuticals News and Research

Patent applications for Shrink's stem cell research and drug discovery tool StemDisc filed

Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA

ICON announces acquisition of Timaq Medical Imaging

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

Health leaders discuss polio, alcohol, childhood obesity at WHA

New MALDI molecular imaging system offers spatial analysis of target metabolites

Groundwater contaminants present potential health concern

Bayer Healthcare Pharmaceuticals presents Phase 3 clinical data on gadobutrol

High family medical bills appear to reduce use of expensive medications: Study

New data on ARIAD's AP24534 and ridaforolimus accepted for presentation at ASCO 2010

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

Clinical data evaluating CAL-101 in patients with hematologic malignancies to be presented at ASCO 2010

China BCT Pharmacy reports 5.2% increase in first-quarter 2010 revenue

Ligand Pharmaceuticals secures milestone and royalty interest in IL-9 antibody program

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010

Smoking cessation treatments effective and safe for people with schizophrenia

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Cord Blood America reviews first quarter results

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence